Revance Releases First Quarter 2016 Results
- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow’s Feet Lines – - Moves Phase 2 Dose-Escalating Trial for RT002 Injectable for Cervical Dystonia into Second Cohort - NEWARK, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Revance …